Compare · ABT vs GYRE
ABT vs GYRE
Side-by-side comparison of Abbott Laboratories (ABT) and Gyre Therapeutics Inc. (GYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and GYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $160.44B, about 227.0x GYRE ($706.8M).
- Over the past year, ABT is down 30.2% and GYRE is down 16.5% - GYRE leads by 13.7 points.
- ABT has been more active in the news (10 items in the past 4 weeks vs 8 for GYRE).
- ABT has more recent analyst coverage (25 ratings vs 3 for GYRE).
- Company
- Abbott Laboratories
- Gyre Therapeutics Inc.
- Price
- $92.11-1.93%
- $6.33-2.84%
- Market cap
- $160.44B
- $706.8M
- 1M return
- +3.38%
- +5.85%
- 1Y return
- -30.23%
- -16.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2006
- News (4w)
- 10
- 8
- Recent ratings
- 25
- 3
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
- Robert W. Baird initiated coverage on Abbott Labs with a new price target
- EVP, GC AND SECRETARY Cushman Elizabeth C. covered exercise/tax liability with 560 units of Common shares without par value, decreasing direct ownership by 1% to 38,013 units (SEC Form 4)
- Abbott hosts conference call for second-quarter earnings
- ALZpath Signs Global Licensing Agreement with Abbott to Advance Blood-Based Alzheimer's Disease Testing
Latest GYRE
- Amendment: SEC Form S-3/A filed by Gyre Therapeutics Inc.
- SEC Form 4 filed by Director Carmichael Gordon
- SEC Form 4 filed by Director Weng Dan
- SEC Form 4 filed by Director Zhang Ping
- SEC Form 4 filed by Director Parry Renate
- SEC Form 4 filed by Director Epstein David M.
- SEC Form 4 filed by Director Nussbaum Rodney L
- Chief Operating Officer Ye Weiguo exercised 11,000 shares at a strike of $0.75 and sold $68,700 worth of shares (11,000 units at $6.25) (SEC Form 4)
- Gyre Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Operating Officer Ye Weiguo exercised 2,800 shares at a strike of $0.75 and sold $17,276 worth of shares (2,800 units at $6.17) (SEC Form 4)